User:Mr. Ibrahem/Sotrovimab
From Wikipedia, the free encyclopedia
Sotrovimab, sold under the brand name Xevudy, is a medication which was used to treat COVID-19 in people who do not need supplemental oxygen but are a high risk of getting severe disease.[5] In this group it decreased the need for hospitalization.[6] It; however, does not appear effective for Omicron BA.2 subvariant and is not recommended in regions were this makes up more than half of cases.[7][8][9] It is given by gradual injection into a vein.[5]
![]() A vial of sotrovimab | |
Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Human |
Target | Spike protein of SARS-CoV-2 |
Clinical data | |
Trade names | Xevudy |
Other names | VIR-7831, GSK4182136 |
AHFS/Drugs.com | Monograph |
License data |
|
Pregnancy category |
|
Routes of administration | Intravenous |
Legal status | |
Legal status |
Common side effects include allergic reactions including anaphylaxis.[5] Anaphylaxis occurs in about 1 in 2,000 people.[5] Safety in pregnancy or breastfeeding is unclear.[4] It is a monoclonal antibody which attaches to the spike protein of SARS-CoV-2 making the virus unable to enter the body’s cells.[5]
Sotrovimab was approved for medical use in Europe in 2021.[5] It has Emergency Use Authorization (EUA) in the United States as of 2021.[4] In the United States it costs 2,100 USD per dose, with this amount paid by the the United States government.[10]